실시간

FierceBiotechRegeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy FierceBiotechVincentage sees 12.4% weight loss for oral GLP-1, will chase Lilly to Chinese regulators PharmaVoiceRace intensifies to lead next wave of obesity drugs as trial results loom FierceBiotechBoston Scientific funnels $1.5B into MiRus, with option to buy TAVR system LabiotechNew antidepressants: Tackling treatment resistant depression Thermo FisherThermo Fisher Scientific Expands PPD Laboratory Services Network With New Bioanalytical Facility In Sweden - BioPharma APAC Thermo FisherThermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - The Joplin Globe FierceBiotechWhere the Promise of NAMs Meets Practice FierceBiotechOhio Discovery Corridor is Attracting the World’s Best in Pediatric Research. Here’s Why Thermo FisherThermo Fisher Scientific’s PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden - Business Wire BioPharma DiveRegeneron immunotherapy combo comes up short in melanoma trial Endpoints NewsRegeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Endpoints News 2026년 5월 18일

Regeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3

Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announc...

Regeneron Pharmaceuticals’ LAG-3 inhibitor called fianlimab has flunked a late-stage skin cancer trial, marking yet another blow for the drug class. The announcement follows a spate of recent clinical setbacks for candidates targeting the LAG-3 ...